Figure 1. Overexpression of IL-17RB is associated with metastasis and poor clinical outcome in pancreatic cancer patients. (A) Representative IHC results of patients with IL-17RB–negative (0%), low positive (< 10%), and high positive (>10%) expression in cancer cells. Bar, 50 µm. Boxes show the enlarged area. (B) Correlation of IL-17RB expression in cancer cells and clinical parameters (2 yr after operation) in 111 pancreatic cancer cases. χ2 test was used. (C) Comparison of the progression free survival (PFS) of patients with different levels of IL-17RB expression using the Kaplan-Meier method. P = 0.035. (D) Univariate and multivariate Cox regression analysis of the influence of IL-17RB expression on the PFS of 111 pancreatic cancer patients after surgical therapy.
Figure 1.

Overexpression of IL-17RB is associated with metastasis and poor clinical outcome in pancreatic cancer patients. (A) Representative IHC results of patients with IL-17RB–negative (0%), low positive (< 10%), and high positive (>10%) expression in cancer cells. Bar, 50 µm. Boxes show the enlarged area. (B) Correlation of IL-17RB expression in cancer cells and clinical parameters (2 yr after operation) in 111 pancreatic cancer cases. χ2 test was used. (C) Comparison of the progression free survival (PFS) of patients with different levels of IL-17RB expression using the Kaplan-Meier method. P = 0.035. (D) Univariate and multivariate Cox regression analysis of the influence of IL-17RB expression on the PFS of 111 pancreatic cancer patients after surgical therapy.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal